These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18295820)

  • 1. Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase.
    Zhang J; Huitema C; Niu C; Yin J; James MN; Eltis LD; Vederas JC
    Bioorg Chem; 2008 Oct; 36(5):229-40. PubMed ID: 18295820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
    Huitema C; Zhang J; Yin J; James MN; Vederas JC; Eltis LD
    Bioorg Med Chem; 2008 May; 16(10):5761-77. PubMed ID: 18407505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro.
    Jain RP; Pettersson HI; Zhang J; Aull KD; Fortin PD; Huitema C; Eltis LD; Parrish JC; James MN; Wishart DS; Vederas JC
    J Med Chem; 2004 Dec; 47(25):6113-6. PubMed ID: 15566280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.
    Zhang J; Pettersson HI; Huitema C; Niu C; Yin J; James MN; Eltis LD; Vederas JC
    J Med Chem; 2007 Apr; 50(8):1850-64. PubMed ID: 17381079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem; 2010 Nov; 18(22):7849-54. PubMed ID: 20947359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
    Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
    Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
    Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
    Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase.
    Li C; Qi Y; Teng X; Yang Z; Wei P; Zhang C; Tan L; Zhou L; Liu Y; Lai L
    J Biol Chem; 2010 Sep; 285(36):28134-40. PubMed ID: 20489209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
    Ghosh AK; Takayama J; Aubin Y; Ratia K; Chaudhuri R; Baez Y; Sleeman K; Coughlin M; Nichols DB; Mulhearn DC; Prabhakar BS; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2009 Aug; 52(16):5228-40. PubMed ID: 19645480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.
    Chen LR; Wang YC; Lin YW; Chou SY; Chen SF; Liu LT; Wu YT; Kuo CJ; Chen TS; Juang SH
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3058-62. PubMed ID: 15896959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro).
    Bacha U; Barrila J; Gabelli SB; Kiso Y; Mario Amzel L; Freire E
    Chem Biol Drug Des; 2008 Jul; 72(1):34-49. PubMed ID: 18611220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.
    Lee CC; Kuo CJ; Ko TP; Hsu MF; Tsui YC; Chang SC; Yang S; Chen SJ; Chen HC; Hsu MC; Shih SR; Liang PH; Wang AH
    J Biol Chem; 2009 Mar; 284(12):7646-55. PubMed ID: 19144641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
    Prior AM; Kim Y; Weerasekara S; Moroze M; Alliston KR; Uy RA; Groutas WC; Chang KO; Hua DH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6317-20. PubMed ID: 24125888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.